Home
PRME
PRME News

Latest Prime Medicine Inc. (PRME) News on April 2, 2025

Why Prime Medicine Stock Was Climbing Higher This Week

Motley Fool

12 days ago

Why Prime Medicine Stock Was Climbing Higher This Week

MT Newswires

13 days ago

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating

Why Prime Medicine Stock Is Soaring Today

Motley Fool

13 days ago

Why Prime Medicine Stock Is Soaring Today

Prime sets sights on liver, lung disease as next target for its gene editing tech

BioPharma Dive

15 days ago

Prime sets sights on liver, lung disease as next target for its gene editing tech

MT Newswires

15 days ago

Prime Medicine Launches Preclinical Program for Liver Treatments

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire

15 days ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

a month ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire

a month ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

3 months ago

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Insider Monkey

3 months ago

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

3 months ago

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

MT Newswires

4 months ago

Prime Medicine Files for Resale of 11 Million Shares

MT Newswires

4 months ago

JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

5 months ago

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

5 months ago

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

12 High-Growth Stocks That Could Deliver Parabolic Returns

Motley Fool

5 months ago

12 High-Growth Stocks That Could Deliver Parabolic Returns

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

GlobeNewswire

5 months ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Why I Keep Buying These 14 Incredible Growth Stocks

Motley Fool

6 months ago

Why I Keep Buying These 14 Incredible Growth Stocks

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

GlobeNewswire

6 months ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Zacks

6 months ago

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Pharmaceutical Technology

6 months ago

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Motley Fool

6 months ago

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

MT Newswires

6 months ago

Sector Update: Health Care Stocks Steady Premarket Monday

MT Newswires

6 months ago

Sector Update: Health Care

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Benzinga

6 months ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

MT Newswires

6 months ago

Prime Medicine Enters Research Collaboration, License Agreement With Bristol Myers Squibb

Prime Medicine Unveils Strategically Focused Pipeline

GlobeNewswire

6 months ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

GlobeNewswire

6 months ago

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Prime to narrow gene editing research as it strikes deal with Bristol Myers

BioPharma Dive

6 months ago

Prime to narrow gene editing research as it strikes deal with Bristol Myers

2 Growth Stocks That Could Make You Richer

Motley Fool

7 months ago

2 Growth Stocks That Could Make You Richer

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

7 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

8 months ago

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

Zacks

8 months ago

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Zacks

8 months ago

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?

Insider Monkey

9 months ago

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Zacks

9 months ago

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade

Zacks

10 months ago

Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade

Prime Medicine to Present at Upcoming Investor Conferences

GlobeNewswire

10 months ago

Prime Medicine to Present at Upcoming Investor Conferences

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

Motley Fool

10 months ago

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

TipRanks

10 months ago

Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

MT Newswires

10 months ago

HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target

MT Newswires

a year ago

Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?

Zacks

a year ago

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?

MT Newswires

a year ago

JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire

a year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

Barrons.com

a year ago

Alphabet Bought Up Two Slumping Stocks

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

GuruFocus.com

a year ago

Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

GlobeNewswire

a year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

What Makes Prime Medicine, Inc. (PRME) a New Buy Stock

Zacks

a year ago

What Makes Prime Medicine, Inc. (PRME) a New Buy Stock

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

GlobeNewswire

a year ago

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

Prime Medicine gets green light for trials of first-ever prime editing drug

Clinical Trials Arena

a year ago

Prime Medicine gets green light for trials of first-ever prime editing drug

MT Newswires

a year ago

Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance

Prime gets FDA green light to begin first trial test of ‘prime editing’

BioPharma Dive

a year ago

Prime gets FDA green light to begin first trial test of ‘prime editing’

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

GlobeNewswire

a year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

GlobeNewswire

a year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

2 Magnificent Growth Stocks With Room to Run

Motley Fool

a year ago

2 Magnificent Growth Stocks With Room to Run

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

InvestorPlace

a year ago

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

14 Stocks With Heavy Insider Buying In 2024

Insider Monkey

a year ago

14 Stocks With Heavy Insider Buying In 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Prime Medicine to Participate in Upcoming Investor Conferences

With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

a year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

GlobeNewswire

a year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

GlobeNewswire

a year ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire

a year ago

Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner

Business Wire

a year ago

Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner

SPX Technologies, Inc. (SPXC) Soars to 52-Week High, Time to Cash Out?

Zacks

a year ago

SPX Technologies, Inc. (SPXC) Soars to 52-Week High, Time to Cash Out?

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 01/29/2024

Director Laura Whitley Acquires 2,000 Shares of Texas Capital Bancshares Inc (TCBI)

GuruFocus.com

a year ago

Director Laura Whitley Acquires 2,000 Shares of Texas Capital Bancshares Inc (TCBI)

Insider Sell: Couchbase Inc's SVP & Chief Revenue Officer Huw Owen Disposes of Shares

GuruFocus.com

a year ago

Insider Sell: Couchbase Inc's SVP & Chief Revenue Officer Huw Owen Disposes of Shares

Energy & Utilities Roundup: Market Talk

The Wall Street Journal

a year ago

Energy & Utilities Roundup: Market Talk

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

GlobeNewswire

a year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Energy Fuels (UUUU) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

a year ago

Energy Fuels (UUUU) Stock Slides as Market Rises: Facts to Know Before You Trade

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

Zacks

a year ago

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

Core Laboratories (CLB) Reports Next Week: What You Should Expect

Zacks

a year ago

Core Laboratories (CLB) Reports Next Week: What You Should Expect

Tilray Brands Completes Acquisition of Truss Beverage Co.

GlobeNewswire

a year ago

Tilray Brands Completes Acquisition of Truss Beverage Co.

Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet

Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock

GlobeNewswire

a year ago

Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock

Earnings Preview: Cadence (CADE) Q4 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Cadence (CADE) Q4 Earnings Expected to Decline

Unpacking Q3 Earnings: Hormel Foods (NYSE:HRL) In The Context Of Other Packaged Food Stocks

StockStory

a year ago

Unpacking Q3 Earnings: Hormel Foods (NYSE:HRL) In The Context Of Other Packaged Food Stocks

Compass Minerals Announces Conference Call to Discuss First-Quarter Fiscal 2024 Results

Business Wire

a year ago

Compass Minerals Announces Conference Call to Discuss First-Quarter Fiscal 2024 Results

With EPS Growth And More, Fresh Del Monte Produce (NYSE:FDP) Makes An Interesting Case

Simply Wall St.

a year ago

With EPS Growth And More, Fresh Del Monte Produce (NYSE:FDP) Makes An Interesting Case

Walgreens, Eli Lilly, Crypto CEOs and more: C-Suite Insights

Yahoo Finance Video

a year ago

Walgreens, Eli Lilly, Crypto CEOs and more: C-Suite Insights

Bel Fuse Celebrates 75 Years of Electronic Solution Excellence and Innovation

GlobeNewswire

a year ago

Bel Fuse Celebrates 75 Years of Electronic Solution Excellence and Innovation

Lemonade (LMND) Outperforms Broader Market: What You Need to Know

Zacks

a year ago

Lemonade (LMND) Outperforms Broader Market: What You Need to Know

Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know

Albertsons Media Collective Selects Criteo to Power its Retail Media Ecosystem

PR Newswire

a year ago

Albertsons Media Collective Selects Criteo to Power its Retail Media Ecosystem

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Business Wire

a year ago

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Business Wire

a year ago

OneSpaWorld Announces Preliminary Fourth Quarter and Fiscal Year 2023 Revenue and EBITDA in line with Guidance and Introduces Fiscal 2024 Revenue and EBITDA Guidance

Abbott, Tandem launch new hybrid closed-loop insulin delivery system

MedTech Dive

a year ago

Abbott, Tandem launch new hybrid closed-loop insulin delivery system

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

GlobeNewswire

a year ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

16 Most Promising Long-Term Stocks According to Analysts

Insider Monkey

a year ago

16 Most Promising Long-Term Stocks According to Analysts

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Zacks

a year ago

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Zacks

a year ago

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Share on Social Networks: